Press coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.0119606278518 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.45% on Tuesday, reaching $67.07. 999,388 shares of the company traded hands. Intercept Pharmaceuticals has a 52-week low of $54.98 and a 52-week high of $147.52. The firm has a 50-day moving average of $85.96 and a 200-day moving average of $108.58. The company’s market capitalization is $1.68 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm’s quarterly revenue was up 459.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($3.14) earnings per share. On average, equities research analysts forecast that Intercept Pharmaceuticals will post ($13.99) earnings per share for the current fiscal year.

ICPT has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and issued a $231.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, June 23rd. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC initiated coverage on shares of Intercept Pharmaceuticals in a research report on Monday, July 10th. They issued a “buy” rating and a $275.00 price objective on the stock. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price objective on the stock in a research report on Tuesday, July 11th. Finally, Cantor Fitzgerald reiterated an “underweight” rating and issued a $69.00 price objective (up from $60.00) on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. Four research analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $153.76.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Intercept Pharmaceuticals (ICPT) Share Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/17/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-intercept-pharmaceuticals-icpt-share-price.html.

In other news, CEO Mark Pruzanski sold 1,532 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO David Shapiro sold 1,250 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the sale, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,278 shares of company stock valued at $592,796. 4.50% of the stock is currently owned by corporate insiders.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.